Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...

Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...

Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...

Like Kymera, I am not prepared to give up on the protein deg story yet, and although a poor set of data, or the exit of Sanofi from the KT-474 program could derail the company's share price ...

Kymera's partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program. Find out the reasons to rate KYMR stock a Buy.

Sanofi has informed Kymera that it will advance KT-485, Kymera's drug candidate targeting IRAK4 for immuno-inflammatory diseases, into clinical studies and not proceed with KT-474.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

However, Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into ...